» Articles » PMID: 34282258

PERK Mediates Resistance to BRAF Inhibition in Melanoma with Impaired PTEN

Overview
Publisher Springer Nature
Specialty Oncology
Date 2021 Jul 20
PMID 34282258
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Targeting mutant BRAF in patients with melanomas harboring this oncogene has been highly successful as a first-line treatment, but other mutations may affect its efficacy and alter the route of acquired resistance resulting in recurrence and poor prognosis. As an evolving strategy, melanoma treatment needs to be expanded to include targets based on newly discovered emerging molecules and pathways. We here show that PERK plays a critical role in BRAF inhibitor-acquired resistance in melanoma with impaired PTEN. Inhibition of PERK by either shRNA or a pharmacological inhibitor blocked the growth of BRAF inhibitor-resistant melanoma with impaired PTEN in vitro and in vivo, suggesting an effective approach against melanomas with mutant BRAF and PTEN deficiency. Our current findings, along with our previous discovery that the AXL/AKT axis mediates resistance to BRAF inhibition in melanoma with wild-type PTEN, provide new insights toward a strategy for combating BRAF inhibition-acquired resistance in BRAF mutant melanoma with different PTEN statuses.

Citing Articles

Development of Personalized Strategies for Precisely Battling Malignant Melanoma.

Isaak A, Clements G, Buenaventura R, Merlino G, Yu Y Int J Mol Sci. 2024; 25(9).

PMID: 38732242 PMC: 11084485. DOI: 10.3390/ijms25095023.


Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.

Chen W, Park J Int J Mol Sci. 2023; 24(19).

PMID: 37834284 PMC: 10573597. DOI: 10.3390/ijms241914837.


PTEN phosphatase inhibits metastasis by negatively regulating the Entpd5/IGF1R pathway through ATF6.

Yu Y, Dai M, Huang L, Chen W, Yu E, Mendoza A iScience. 2023; 26(2):106070.

PMID: 36824269 PMC: 9942123. DOI: 10.1016/j.isci.2023.106070.


PTEN Dual Lipid- and Protein-Phosphatase Function in Tumor Progression.

Liu A, Zhu Y, Chen W, Merlino G, Yu Y Cancers (Basel). 2022; 14(15).

PMID: 35954330 PMC: 9367293. DOI: 10.3390/cancers14153666.


Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity.

Salvagno C, Mandula J, Rodriguez P, Cubillos-Ruiz J Trends Cancer. 2022; 8(11):930-943.

PMID: 35817701 PMC: 9588488. DOI: 10.1016/j.trecan.2022.06.006.


References
1.
Healy E, Rehman I, Angus B, Rees J . Loss of heterozygosity in sporadic primary cutaneous melanoma. Genes Chromosomes Cancer. 1995; 12(2):152-6. DOI: 10.1002/gcc.2870120211. View

2.
Salaroglio I, Panada E, Moiso E, Buondonno I, Provero P, Rubinstein M . PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy. Mol Cancer. 2017; 16(1):91. PMC: 5427528. DOI: 10.1186/s12943-017-0657-0. View

3.
Beck D, Niessner H, Smalley K, Flaherty K, Paraiso K, Busch C . Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal. 2013; 6(260):ra7. PMC: 3698985. DOI: 10.1126/scisignal.2003057. View

4.
Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

5.
Chen W, Zhu G, Pfaffenbach K, Kanel G, Stiles B, Lee A . GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN. Oncogene. 2013; 33(42):4997-5005. PMC: 3994182. DOI: 10.1038/onc.2013.437. View